On July 12, 2023 OncoBone Ventures reported its founders participated in writing a newly published invited review article for the Journal Frontiers in Immunology (Press release, OncoBone Ventures, JUL 12, 2023, View Source [SID1234636481]). The publication titled ‘Insights into immuno-oncology drug development landscape with focus on bone metastasis’ provides a comprehensive review of the competitive drug development landscape for bone metastasis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The full publication can be found from the following link: Kähkönen et al., Frontiers in Immunology, Vol 14, 2023.

Tiina Kähkönen, CSO of OncoBone Ventures and the lead author of the publication says: ‘It was a great pleasure to be invited to contribute a publication in Frontiers in Immunology. By using a sophisticated drug development database we were able to provide for the first time a comprehensive analysis of the drug development landscape for bone metastasis. This information is very important not only for OncoBone Ventures, but also globally for researchers working in the bone metastasis field.’